September 8th 2023
Brad S. Kahl, MD, discusses the potential for BTK inhibitors to shift the frontline treatment setting in mantle cell lymphoma.
July 20th 2022
Brad S. Kahl, MD, discusses current best practices for the treatment of older patients with mantle cell lymphoma, as well as where the treatment paradigm might lead in the future.
October 15th 2021
Brad S. Kahl, MD, discusses the potential utility of frontline CAR T-cell therapy in mantle cell lymphoma.
September 22nd 2021
Brad S. Kahl, MD, discusses a potential limitation of frontline combination strategies with BTK inhibitors in mantle cell lymphoma.
September 15th 2021
Brad S. Kahl, MD, discusses patient selection for intensive vs non-intensive treatment strategies in mantle cell lymphoma.
September 10th 2021
Brad S. Kahl, MD, discusses the potential utility of BTK inhibitor–based combinations in the frontline setting of mantle cell lymphoma.
July 7th 2021
Brad S. Kahl, MD, discusses the differences between mechanisms of action of PI3K inhibitors in follicular lymphoma.
July 6th 2021
Brad S. Kahl, MD, discusses selecting between PI3K inhibitors in follicular lymphoma.
December 8th 2020
Brad S. Kahl, MD, discusses remaining challenges with CAR T-cell therapy in diffuse large B-cell lymphoma.
June 12th 2020
Brad S. Kahl, MD, discusses findings from the phase 2 L-MIND study in diffuse large B-cell lymphoma.
June 14th 2017
Brad S. Kahl, MD, professor, Department of Medicine, Oncology Division, Washington University School of Medicine, discusses ADCT-402 for patients with relapsed/refractory B-cell lineage non-Hodgkin lymphoma.